A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone. (Q34746876)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Francis K Yoshimoto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Mariana Garrido

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sunil K Upadhyay

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Eugene Bratoeff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Richard J Auchus

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

6 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Steroid Biochemistry and Molecular Biology

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

1-10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

The action of cytochrome b(5) on CYP2E1 and CYP2C19 activities requires anionic residues D58 and D65.

7 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

CYP17 Mutation E305G Causes Isolated 17,20-Lyase Deficiency by Selectively Altering Substrate Binding

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

5α-reduced C21 steroids are substrates for human cytochrome P450c17

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4272579

EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24508512

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24508512

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.JSBMB.2014.01.013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24508512%20AND%20SRC:MED&resulttype=core&format=json